The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis
Open accessAbstract
Background/Aims: Epithelial-to-mesenchymal transition (EMT) plays a crucial role in hepatic fibrogenesis and liver repair in chronic liver disease. Our research highlights the antifibrotic potential of placenta-derived mesenchymal stem cells (PD-MSCs) and the role of phosphatase of regenerating liver-1 (PRL-1) in promoting liver regeneration.Methods: We evaluated the efficacy of PD-MSCs overexpressing PRL-1 (PD-MSCsPRL-1) in a bile duct ligationinduced rat injury model, focusing on their ability to regulate EMT.Results: PD-MSCsPRL-1 significantly reduced mesenchymal markers by downregulating TGFB1/SMAD2, outperforming naïve PD-MSCs. The transplantation of PD-MSCsPRL-1 enhanced BMP7/SMAD1/5 expression, promoting epithelial marker expression and stimulating BMP7 within hepatocytes, modulating downstream SMAD signaling. Importantly, further validation confirmed that PRL-1 directly interacts with BMP7 in hepatocytes.Conclusions: PRL-1 expression in PD-MSCsPRL-1 restores TGFB1/BMP7 balance, promoting hepatic regeneration through mesenchymal-to-epithelial transition. These findings highlight the therapeutic potential of engineered MSCs for liver disease and suggest innovative strategies for future stem cell therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a BDL-injured rat model, PRL-1-overexpressing PD-MSCs demonstrated a suppressed mesenchymal phenotype and enhanced immunomodulatory properties.
“In a BDL-injured rat model, PRL-1-overexpressing PD-MSCs (PD-MSCsPRL−1) demonstrated a suppressed mesenchymal phenotype and enhanced immunomodulatory properties [362].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [362]
PRL-1-overexpressing PD-MSCs promoted liver regeneration by facilitating mesenchymal-to-epithelial transition and restoring TGFβ1/BMP7 balance.
“These PD-MSCsPRL−1 promoted liver regeneration by facilitating mesenchymal-to-epithelial transition (MET) and restoring TGFβ1/BMP7 balance.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [362]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair
Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., et al. (2010) · Cell Research · doi:10.1038/cr.2010.44 · Cited by 575
Flagged first, then by citations
Research works printed but not linked: 30
- 10.1172/jci39104 · DOI · Paper page
- 10.1159/000147748 · DOI
- 10.1016/j.jhep.2018.05.008 · DOI · Paper page
- 10.3892/br.2016.578 · DOI
- 10.4254/wjh.v6.i4.207 · DOI
- 10.3727/096368910x514198 · DOI
- 10.1002/stem.1396 · DOI
- 10.1155/2017/5180579 · DOI
- 10.1186/s12967-020-02234-x · DOI
- 10.1517/14728222.2014.892926 · DOI
- 10.18632/oncotarget.12116 · DOI
- 10.1186/s13287-020-02029-3 · DOI
- 10.1002/jcb.22873 · DOI
- 10.15283/ijsc20117 · DOI
- Kountouras, 1984, Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat, 305
- 10.3390/ijms20215299 · DOI
- 10.1016/j.jhep.2019.11.013 · DOI · Paper page
- 10.1002/hep.23529 · DOI
- 10.1038/nm888 · DOI
- 10.1136/gutjnl-2014-306842 · DOI
- 10.3390/ijms20112767 · DOI
- 10.1089/scd.2012.0395 · DOI
- Wang, 2013, Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats, 897
- 10.3892/mmr.2017.7785 · DOI
- 10.3390/cells8101130 · DOI
- 10.1038/s41374-018-0069-9 · DOI
- 10.7150/ijms.5765 · DOI
- 10.1371/journal.pone.0061340 · DOI
- 10.1096/fj.06-6837com · DOI
- 10.1006/bbrc.1998.8291 · DOI
Cited by
Sorted by citations
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
Metadata
- Authors
- Kim, J. Y., Park, H., Park, S. Y., Kim, S. H., Lim, J. Y., Lee, K. S., Bae, S. H., & Kim, G. J.
- Affiliations
- CHA University (KR)
- Korea University (KR)
- Catholic University of Pusan (KR)
- Catholic University of Korea (KR)
- Corresponding author
- Kim, Gi Jin
- Venue
- Clinical and Molecular Hepatology
- Published
- 2025-07-01
- Volume
- 31
- Issue
- 3
- Pages
- 823-840
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- PMC
- PMC12260616
- OpenAlex
- W4406715899
- Cited by
- 7
- References
- 1
- Citations by year
- 2026: 4 · 2025: 3
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Molecular Hepatology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (RS-2023-00279247)
- Ministry of Science and ICT
- Korean Fund for Regenerative Medicine (RS-2022-00070304)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- placenta-derived mesenchymal stem cells, liver fibrosis, epithelial-mesenchymal transition, mesenchymal-epithelial transition, BMP-7, Smad1/5 signaling, bile duct ligation, liver regeneration, engineered stem cells, stem cell therapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Humans, Liver Cirrhosis, Liver Regeneration, Male, Placenta, Pregnancy, Signal Transduction, Protein Tyrosine Phosphatases, Rats, Sprague-Dawley, Hepatocytes, Mesenchymal Stem Cell Transplantation, Rats, Smad Proteins, Transforming Growth Factor beta1, Bone Morphogenetic Protein 7, Epithelial-Mesenchymal Transition, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
